Targeted therapies for sarcomas: new roles for the pathologist

Tariq Al-Zaid1, Neeta Somaiah, Alexander J Lazar

  • 1Department of Pathology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Histopathology
|October 15, 2013
PubMed

Insights

Pathologists play a crucial role in diagnosing and grading sarcomas. Understanding sarcoma genetics is vital for targeted therapies and improved patient care, expanding the pathologist

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Sarcomas are diverse cancers originating from connective tissues.
  • Traditional pathology focuses on diagnosis and grading for treatment.
  • Emerging targeted therapies necessitate understanding molecular alterations.

Purpose of the Study:

  • To review the evolving role of pathologists in sarcoma care.
  • To highlight the importance of molecular characterization in sarcomas.
  • To discuss targeted therapies and their impact on patient management.

Main Methods:

  • Literature review of sarcoma pathogenetic mechanisms.
  • Enumeration of molecular derangements in soft tissue sarcoma.
  • Discussion of targeted agents in clinical use or investigation.

Main Results:

  • Pathologists' roles extend beyond diagnosis to molecular profiling.
  • Awareness of genetic features is key for multidisciplinary sarcoma care.
  • Specific sarcomas like DFSP and GIST exemplify the impact of molecular insights.

Conclusions:

  • Molecular characterization by pathologists significantly influences sarcoma treatment.
  • Targeted therapies offer new avenues for managing various sarcomas.
  • An integrated approach combining pathology and molecular genetics optimizes patient outcomes.